Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on JLP-1310 Pharmacokinetics in Healthy Male Volunteers
NCT02449187Phase 1Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Aug 2017
- Primary completion
- Sep 2017
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of JLP-1310 in type 2 diabetes mellitus (T2DM) and hyperlipidemia (2 arms), sponsored by Jeil Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to the last measurable concentration. Started Aug 2017; status: completed.
02
Drugs
JLP-1310
03
Conditions
type 2 diabetes mellitus (T2DM)hyperlipidemia
Beyond the preview
Go deeper on NCT02449187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02449187.